公开(公告)号：WO2012097173A2

公开(公告)日：2012-07-19

申请号：PCT/US2012/021110

申请日：2012-01-12

Applicant: VENTIRX PHARMACEUTICALS, INC. ,  HOWBERT, James Jeffry ,  HERSHBERG, Robert

Inventor： HOWBERT, James Jeffry ,  HERSHBERG, Robert

IPC: C07D223/16 ,  C07D403/10 ,  A61K31/55 ,  A61P35/00 ,  A61P29/00

CPC classification number: C07D295/192 ,  A61K31/55 ,  C07D223/16 ,  C07D401/04 ,  C07D403/10 ,  C07D413/10 ,  C07D487/04

Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease.

公开(公告)号：WO2012045089A2

公开(公告)日：2012-04-05

申请号：PCT/US2011/054652

申请日：2011-10-03

Applicant: VENTIRX PHARMACEUTICALS, INC. ,  HERSHBERG, Robert

Inventor： HERSHBERG, Robert

IPC: A61K31/55 ,  A61K9/20 ,  A61K9/48 ,  A61K9/16 ,  A61P37/00

CPC classification number: A61K31/55 ,  A61K9/0043

Abstract: The present invention is directed generally to a TLR8 agonist VTX-378, for use in the treatment or prevention of allergic diseases, including allergic rhinitis.

Abstract translation: 本发明一般涉及TLR8激动剂VTX-378，其用于治疗或预防过敏性疾病，包括过敏性鼻炎。

公开(公告)号：WO2011133819A3

公开(公告)日：2012-03-08

申请号：PCT/US2011033500

申请日：2011-04-21

Applicant: VENTIRX PHARMACEUTICALS INC ,  HERSHBERG ROBERT

Inventor： HERSHBERG ROBERT

IPC: A61K31/55 ,  A61K39/395 ,  A61P35/00 ,  A61P35/02

CPC classification number: A61K31/55 ,  A61K39/39 ,  A61K39/395 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2300/00 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/3046 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/732

Abstract: The application relates to method of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided for administering to subject to a subject in need thereof a therapeutic antibody in conjunction with an ADCC enhancer molecule.

Abstract translation: 本申请涉及在接受治疗性单克隆抗体治疗的受试者中增加抗体依赖性细胞毒性的方法。 在一些实施方案中，提供了用于施用以治疗有需要的受试者与ADCC增强子分子结合的治疗性抗体的方法。

公开(公告)号：WO2011133819A2

公开(公告)日：2011-10-27

申请号：PCT/US2011/033500

申请日：2011-04-21

Applicant: VENTIRX PHARMACEUTICALS, INC. ,  HERSHBERG, Robert

Inventor： HERSHBERG, Robert

IPC: A61K31/55 ,  A61K39/395 ,  A61P35/02 ,  A61P35/00

CPC classification number: A61K31/55 ,  A61K39/39 ,  A61K39/395 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2300/00 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/3046 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/732

Abstract: The application relates to method of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided for administering to subject to a subject in need thereof a therapeutic antibody in conjunction with an ADCC enhancer molecule.

Abstract translation: 本申请涉及在接受治疗性单克隆抗体治疗的受试者中增加抗体依赖性细胞毒性的方法。 在一些实施方案中，提供了用于施用以治疗有需要的受试者与ADCC增强子分子结合的治疗性抗体的方法。

公开(公告)号：WO2011022509A2

公开(公告)日：2011-02-24

申请号：PCT/US2010/045935

申请日：2010-08-18

Applicant: VENTIRX PHARMACEUTICALS, INC. ,  ARRAY BIOPHARMA, INC ,  HOWBERT, James, Jeffry ,  DIETSCH, Gregory ,  HERSHBERG, Robert ,  BURGESS, Laurence, E. ,  DOHERTY, George, A. ,  EARY, C. Todd ,  GRONEBERG, Robert, D. ,  JONES, Zachary

Inventor： HOWBERT, James, Jeffry ,  DIETSCH, Gregory ,  HERSHBERG, Robert ,  BURGESS, Laurence, E. ,  DOHERTY, George, A. ,  EARY, C. Todd ,  GRONEBERG, Robert, D. ,  JONES, Zachary

IPC: C07D403/10 ,  C07D403/14 ,  C07D401/14 ,  C07D223/14 ,  A61K31/4025 ,  A61K31/55 ,  A61P35/00 ,  A61P31/00

CPC classification number: C07D223/16 ,  A61K31/4025 ,  A61K31/55 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D403/14

Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll- like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.

Abstract translation: 提供用于调节通过Toll样受体TLR7和/或TLR8的信号传导的组合物和方法。 该组合物和方法可用于治疗或预防疾病，包括癌症，自身免疫性疾病，感染性疾病，炎症性疾病，移植排斥反应和移植物抗宿主疾病。

公开(公告)号：WO2010014913A8

公开(公告)日：2010-04-01

申请号：PCT/US2009052422

申请日：2009-07-31

Applicant: VENTIRX PHARMACEUTICALS INC ,  HOWBERT J JEFFRY ,  DUVVURI MURALIKRISHNA ,  HERSHBERG ROB ,  DIETSCH GREG

Inventor： HOWBERT J JEFFRY ,  DUVVURI MURALIKRISHNA ,  HERSHBERG ROB ,  DIETSCH GREG

IPC: A61K39/395

CPC classification number: A61K31/55 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/19 ,  A61K31/724 ,  A61K47/40 ,  A61K47/48969 ,  A61K47/6951 ,  B82Y5/00 ,  C07D223/16 ,  C08B37/0012

Abstract: The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.

Abstract translation: 本发明一般涉及用于治疗癌症，优选实体瘤和淋巴瘤的TLR激动剂，优选TLR7或TLR8激动剂的稳定制剂。 具体地，本发明涉及高达50mg / ml的包含环糊精的TLR激动剂的稳定制剂。

公开(公告)号：IL259040D0

公开(公告)日：2018-06-28

申请号：IL25904018

申请日：2018-04-30

Applicant: VENTIRX PHARMACEUTICALS INC

IPC: A61K20060101

Abstract: The application relates to methods of inducing antitumor immune responses in a subject having cancer. In some embodiments, methods are provided for administering to a subject in need thereof a TLR8 agonist and a PD1-1/PD-L1 antagonist, optionally including one or more additional therapeutic agents.

公开(公告)号：IL218193A

公开(公告)日：2017-10-31

申请号：IL21819312

申请日：2012-02-19

Applicant: ARRAY BIOPHARMA INC ,  VENTIRX PHARMACEUTICALS INC

IPC: A61K20060101 ,  A61P20060101 ,  C07D20060101

公开(公告)号：MX351464B

公开(公告)日：2017-10-16

申请号：MX2013003697

申请日：2011-10-03

Applicant: VENTIRX PHARMACEUTICALS INC STAR

Inventor： HERSHBERG ROBERT

IPC: A61K31/55 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61P37/00

Abstract: La presente invención está dirigida en general a un agonista de TLR8, el VTX-378, para el uso en el tratamiento o la prevención de enfermedades alérgicas, incluyendo rinitis alérgica.

公开(公告)号：MX348935B

公开(公告)日：2017-07-03

申请号：MX2013008220

申请日：2012-01-12

Applicant: VENTIRX PHARMACEUTICALS INC

Inventor： GRONEBERG ROBERT D ,  JOSEPH P LYSSIKATOS ,  HERSHBERG ROBERT ,  HOWBERT JAMES JEFFRY ,  BURGESS LAURENCE E ,  YANG HONG WOON ,  DOHERTY GEORGE A ,  EARY CHARLES TODD ,  JONES ZACHARY

IPC: C07D223/14 ,  A61K31/55 ,  A61P37/00 ,  C07D243/14 ,  C07D401/12 ,  C07D403/10 ,  C07D403/12

Abstract: Se proveen composiciones y métodos útiles para modular la señalización a través de los receptores de tipo TolI TLR7 y/o TLR8; las composiciones y métodos se usan en el tratamiento o prevención de enfermedades que incluyen el cáncer, enfermedades auto inmunes, enfermedades fibróticas, enfermedades cardiovasculares, enfermedades infecciosas, trastorno inflamatorio, rechazo a injertos, o enfermedad de injerto contra huésped.